Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2022-12-19 00:00:00 ET · period of report 2022-12-15 · accession 0001127602-22-027894 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-19 | 2022-12-15 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | S - Sale | $10.90 | -14.1K | 887.7K | -2% | -$153.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-15 | S | D | 14,100 | $10.90 | 887,730 | D | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 30,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. (F2) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.39. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |